[CAS NO. 1802363-75-2] Metallo-β-lactamase-IN-9
PRODUCTS SPECIFICATIONS [1802363-75-2]
DESCRIPTION [1802363-75-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 332.34 |
| Molecular Formula | C13H12N6O3S |
| SMILES | OCC1=CC=C(C=C1)C2=CC=NC(S(=O)(N)=O)=C2C3=NN=NN3 |
Summary
Metallo-β-lactamase-IN-9 (Compound 23) is a pan metallo-beta-lactamase ( MBL ) inhibitor with IC 50 s of 35, 269 and 369 nM against NDM-1 , VIM-1 and IMP-1 , respectively [1] .
IC50 & Target
IC50: 35 nM (NDM-1), 269 nM (VIM-1), 369 nM (IMP-1) [1]
In Vivo
Metallo-β-lactamase-IN-9 (Compound 23) (10 and 50 mg/kg; s.c.; three times a day for 1 day) reduces bacterial burden in both the spleen and kidney in combination with
Imipenem
(HY-B1369A) in a
Klebsiella pneumoniae
MB9249 infection mice model
[1]
.
Mouse Pharmacokinetic Properties of Metallo-β-lactamase-IN-9 (Compound 23)
d
[1]
| dose a (iv, mpk) | AUC (μM·h) | MRT (h) | V dss (L/kg) | Cl (mL/min/kg) |
| 5 a | 27.08 | 5.2 | 2.97 | 9.33 |
| dose (sc, mg/kg) | AUC (μM·h) | C max (μM) | T max (h) |
| 10 b | 27.42 | 13.4 | 0.83 |
| 50 c | 111.28 | 69.1 | 0.5 |
a Formulation, 1.0 mg/mL 23 in 20% DMSO/60% PEG400/20% water (solution) with dose volume of 5 mL/kg.
b Formulation, 1.0 mg/mL of 23 in 30% captisol (solution) with dose volume 10 mL/kg.
c Formulation, 5.0 mg/mL of 23 in 30% captisol (solution) with dose volume of 10 mL/kg.
d AUC, area under the curve; Cl, clearance; iv, intravenous, MRT, mean residence time; V dss , volume of distribution at steady state.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Cytoxan-treated DBA-2 mice, Klebsiella pneumoniae MB9249 infection model [1] |
| Dosage: | 10 and 50 mg/kg, in combination with 5mg/kg Imipenem (HY-B1369A) |
| Administration: | Subcutaneous injection, three times a day for 1 day |
| Result: | Demonstrated reduction of bacterial burden in both the spleen and kidney to a greater extent while combining with Imipenem (HY-B1369A) relative to Imipenem (HY-B1369A) alone. |
| Animal Model: | C57BL/6 mice [1] |
| Dosage: | Intravenous and subcutaneous injection |
| Administration: | 5, 10 and 50 mg/kg (Pharmacokinetic Analysis) |
| Result: | Showed good pharmacokinetic properties. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.